Rapport Therapeutics Q3 2026 Results: Net Loss of $40.2M, Loss Widens
Rapport Therapeutics is a clinical-stage biotechnology company that has incurred significant financial losses since inception and expects to continue doing so. As of November 2, 2026, the company had 59,279,630 shares of common stock outstanding and is focused on developing its lead product candidate, RAP-219, for neurological disorders.
- Key figure
- Net loss $40.2M